Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers

PLoS Clinical Trials

Volumn 2, Issue 1, 2007, Pages

  Mzayek, Fawaz ^a,b   Deng, Haiyan ^a   Mather, Frances J ^a   Wasilevich, Elizabeth C ^a,b,d   Liu, Huayin ^a   Hadi, Christiane M ^a   Chansolme, David H ^a,e   Murphy, Holly A ^a   Melek, Bekir H ^a   Tenaglia, Alan N ^a,e   Mushatt, David M ^a   Dreisbach, Albert W ^a,c   Lertora, Juan J L ^a,c,f   Krogstad, Donald J ^a,c  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TULANE UNIVERSITY   (United States)

^c Charity Hospital General Clinical Research Center   (United States)

^d MICHIGAN DEPARTMENT OF COMMUNITY HEALTH   (United States)

^e National Institutes of Health ^*

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AQ 13; CHLOROQUINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLURRED VISION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG URINE LEVEL; EYE DISEASE; FEMALE; HEADACHE; HEARING IMPAIRMENT; HEMATOLOGIC DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOLTER MONITORING; HUMAN; HUMAN EXPERIMENT; LIVER DISEASE; LIVER FUNCTION TEST; MACULOPAPULAR RASH; MALARIA; MALE; MEAN RESIDENCE TIME; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRURITUS; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; VISUAL IMPAIRMENT; VOLUNTEER; VOMITING;

EID: 34249904428     PISSN: None     EISSN: 15555887     Source Type: Journal    
DOI: 10.1371/journal.pctr.0020006     Document Type: Article

References (53)

1. Breman JG, Alilo MS, Mills A (2004) Conquering the intolerable burden of malaria: What's new, what's needed: A summary. AmJ Trop Med Hyg 71:1-15.
2. World Health Organization Expert Committee on Malaria (2000). World Health Organization Expert Committee on Malaria (2000) Geneva: WHO. WHO Tech Rep Ser 892: i-v, 1-74.
3. Baird JK (2005) Effectiveness of antimalarial drugs. N Engl J Med 352: 1565-1577.
4. White NJ (1996) The treatment of malaria. N Engl J Med 335: 800-806.
5. Wellems TE, Plowe CV (2001) Chloroquine-resistant malaria. J Infect Dis 184: 770-776.
6. Moore DV, Lanier JE (1961) Observations on two Plasmodium falciparum infections with abnormal response to chloroquine. AmJ Trop Med Hyg 10: 5-9.
7. Harinasuta T, Migasen S, Bunnag D (1962) UNESCO First Regional Symposium on Scientific Knowledge of Tropical Parasites [report]. 1962 Nov 5-9. Singapore, Malaysia, University of Singapore. pp 143-153.
8. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, et al. (2000) Mutations in the P. falciparum digestive vacuole transmembrane protein pfcrt and evidence for their role in chloroquine resistance. Mol Cell 6: 861-871.
9. Trape JF (2001) The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg 64 (Suppl 1-2): 12-17.
10. Krogstad DJ (1996) Malaria as a re-emerging disease. Epidemiol Rev 18: 77-89.
11. De D, Krogstad FM, Cogswell FB, Krogstad DJ (1996) Aminoquinolines that circumvent resistance in Plasmodium falciparum in vitro. Am J Trop Med Hyg 55: 579-583.
12. Ridley RG, Hofheinz W, Matile H, Jaquet C, Dorn A, et al. (1996) 4-Aminoquinoline analogs of chloroquine with shortened side chains retain activity against chloroquine-resistant Plasmodium falciparum. Antimicrob Agents Chemother 40: 1846-1854.
13. De D, Krogstad FM, Byers LD, Krogstad DJ (1998) Structure-activity relationships (SARs) among 7-substituted 4-aminoquinolines. J Med Chem 41: 4918-4926.
14. Schmidt LH(1986) Compatibility of relapse patterns of Plasmodium cynomolgi infections in rhesus monkeys with continuous cyclical development and hypnozoite concepts of relapse. Am J Trop Med Hyg 35: 1077-1099.
15. Campbell CC, Collins WE, Milhous WK, Roberts JM, Armstead A (1986) Adaptation of the Indochina I/CDC strain of Plasmodium falciparum to the squirrel monkey (Saimiri sciureus) Am J Trop Med Hyg 35: 472-475.
16. Riccio FS, Lee PS, Winegar RA, De D, Krogstad DJ, et al. (2001) Genetic toxicology testing of the antimalarial drug chloroquine and a new analog, AQ-13. Environ Mol Mutagen 38: 69-79.
17. Ramanathan-Girish S, Catz P, Creek MR, Wu B, Thomas D, et al. (2004) Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgous macaques. Intl J Toxicol 23: 179-189.
18. Krogstad DJ, Litterst CA (1998) Aminoquinolines active against CQ-resistant Plasmodium falciparum. Investigational New Drug Application 55,670.
19. Winstanley PA, Ward SA, Snow RW (2002) Clinical status and implications of antimalarial drug resistance. Microbes Infect 4: 157-164.
20. Goodman CA, Mills AJ (1999) The evidence base on the cost-effectiveness of malaria control measures in Africa. Health Policy Planning 14: 301-312.
21. Sachs JD (2002) A new global effort to control malaria. Science 298: 122-124.
22. Gil PJ, Nogueira F, Stromberg-Norklit J, Lindberg J, Carrrolo M, et al. (2003) Detection of atovaquone and Malarone resistance conferring mutations in Plasmodium falciparum cytochrome b gene (cytb). Mol Cell Probes 17: 85-89.
23. Wichmann O, Muehlberger N, Jelinek T, Alifrangis M, Peyerl-Hofffman G, et al. (2004) Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. J Infect Dis 190: 1541-1546.
24. Toovey S, Jamieson A (2004) Audiometric changes associated with the treatment of complicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg 98: 261-267.
25. Meshnick SR (2002) Artemisinin: Mechanisms of action, resistance and toxicity. Intl J Parasitol 32: 1655-1660.
26. Deng H, Krogstad FM, Liu H, Krogstad DJ (2006) Sensitive fluorescence HPLC assay for AQ-13, a candidate antimalarial, that also detects chloroquine and N-dealkylated metabolites. J Chromatogr B 833: 122-128.
27. Ahnve S (1985) Correction of the QT interval for heart rate: review of different formulas and the use of Bazett's formula in myocardial infarction. Am Heart J 109: 568-574.
28. Bustos MD, Gay F, Diquet B, Thomare P, Warot D (1994) The pharmacokinetics and electrocardiographic effects of chloroquine in healthy subjects. Trop Med Parasitol 45: 83-86.
29. Looareesuwan S, White NJ, Chantavanich P, Edwards G, Nicholl DD, et al. (1986) Cardiovascular toxicity and distribution kinetics of intravenous chloroquine. Br J Clin Pharmacol 22: 31-36.
30. Looareesuwan S, White NJ, Chantavanich P, Edwards G, Nichool DD, et al. (2004) Drugs for parasitic infections. Med Lett Drugs Ther 46: 1-12.
31. Taylor WRJ, White NJ (2004) Antimalarial drug toxicity: A review. Drug Safety 27: 25-61.
32. Mying HY, Tipmanee P, Nosten F, Day NPJ, Pukrittayakamee S, et al. (2004) A systematic overview of published antimalarial drug trials. Trans R Soc Trop Med Hyg 98: 73-81.
33. McIntosh HM, Greenwood BM (1998) Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine as a treatment for uncomplicated malaria - A systematic review. Ann Trop Med Parasitol 93: 265-270.
34. McIntosh HM, Greenwood BM (2000) Drugs for rheumatoid arthritis. Med Lett Drugs Ther 42: 57-64.
35. Gabrielsson J, Weiner D (1997) Pharmacokinetic and pharmacodynamic data analysis: Concepts and applications. 2nd Ed. Stockholm: Swedish Pharmaceutical Society. pp. 139-152.
36. Hilts PJ (2003) Protecting America's health: The FDA, business, and one hundred years of regulation. Chapel Hill: University of North Carolina Press. 343 p.
37. FDA Backgrounder (1999) Milestones in US food and Drug Law History. Available at: http://www.cfsan.fda.gov/mileston.html. Accessed: 5 December 2006.
38. Avina-Zubieta JA, Galindo-Rodriguez G, Newman S, Suarez-Almazor MF, Russell AS (1998) Long-term effectiveness of antimalarial drugs in rheumatic diseases. Ann Rheum Dis 57: 583-587.
39. White NJ (1985) Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet 10: 187-215.
40. Ducharme J, Farinotti R (1996) Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advances. Clin Pharmacokinet 31: 257-274
41. Gustafsson LL, Walker O, Alvan G, Beermann B, Estevez F, et al. (1983) Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol 15: 471-479.
42. Frisk-Holmberg M, Bergqvist Y, Termond E, Domeij-Nyberg B (1984) The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects. Eur J Clin Pharmacol 26: 521-530.
43. Krishna S, White NJ (1996) Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet 30: 263-299.
44. Dua VK, Gupta NC, Kar PK, Edwards G, Singh N, Sharma VP (2002) Pharmacokinetics of chloroquine in Indian tribal and non-tribal healthy volunteers and patients with Plasmodium falciparum malaria. Current Science 83: 1128-1131.
45. Gustafsson LL, Lindstrom B, Grahnen A, Alvan G (1987) Chloroquine excretion following malaria prophylaxis. Br J Clin Pharmacol 24: 221-224.
46. Reece M, Prawitt D, Landers J, Kast C, Gros P, et al. (1998) Functional characterization of ORCTL2-An organic cation transporter expressed in the renal proximal tubules. FEBS Lett 433: 245-250.
47. Projean D, Baune B, Farinotti R, Filinois JP, Beaune P, et al. (2003) In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4 and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Disp 31: 748-754.
48. Benavides-Haro DE, Sanchez-Chapula JA (2000) Chloroquine blocks the background potassium current in guinea pig atrial myocytes. Arch Pharmacol 361: 311-318.
49. Sanchez-Chapula JA, Salinas-Stefanon E, Torres-Jacome J, Benavides-Haro DE, Navarro-Polanco RA (2001) Blockade of currents by antimalarial drug chloroquine in feline ventricular myocytes. J Pharmacol Exptl Therapeutics 297: 437-445.
50. Riou B, Barriot P, Rimailho A, Baud FJ (1998) Treatment of severe chloroquine poisoning. N Engl J Med 318: 1-6.
51. Clemessy JL, Favier C, Borron SW, Hantson PE, Vicaut E, et al. (1995) Hypokalemia related to acute chloroquine ingestion. Lancet 346: 877-880.
52. Shah RR (2002) The significance of QT interval in drug development. Br J Clin Pharmacol 54: 188-202.
53. Witchel HJ, Hancox JC, Nutt DJ (2003) Psychotropic drugs, cardiac arrhythmia and sudden death. J Clin Psychopharmacol 23: 58-77.